Tag Archives: MARA

30 Stocks Moving In Friday's Mid-Day Session

ShiftPixy Inc (NASDAQ: PIXY) shares climbed 97 percent to $4.27 following Q4 earnings report. ShiftPixy reported sales of $20.244 million in the fourth quarter, up from $8.46 million year-over-year. The company sees first quarter gross billings of $40 million.
Longfin Corp (NASDAQ: LFIN) shares climbed 56.8 percent to $8.45 after the company announced agreement to acquire Ziddu.com.
Diana Containerships Inc (NASDAQ: DCIX) shares rose 22.59 percent to $5.97 after falling 7.06 percent on Thursday.
Riot Blockchain, Inc. (NASDAQ: RIOT) shares climbed 14.51 percent to $28.605 after gaining 8.47 percent on Thursday.
Wins Finance Holdings Inc (NASDAQ: WINS) shares gained 14.2 percent to $136.00.
Educational Development Corporation (NASDAQ: EDUC) shares rose 13.1 percent to $16.00 after the company reported Q3 and year-to-date revenue.
Crocs, Inc. (NASDAQ: CROX) climbed 12.4 percent to $12.30. Stifel Nicolaus upgraded Crocs from Hold to Buy.
TiGenix NV (NASDAQ: TIG) gained 12.4 percent to $24.36. Takeda and TiGenix disclosed that Cx601 has received a positive CHMP opinion for treatment of complex perianal fistulas in Crohn's disease. Mesoblast has granted Tigenix exclusive global patent license to use adipose-derived mesenchymal stem cells in local treatment of fistulae.
Marathon Patent Group Inc (NASDAQ: MARA) jumped 10.8 percent to $6.0206 after falling 4.57 percent on Thursday.
Professional Diversity Network Inc (NASDAQ: IPDN) shares rose 10 percent to $4.10.
Under Armour Inc (NYSE: UAA) shares jumped 9 percent to $15.06. Stifel Nicolaus upgraded Under Armour from Hold to Buy.
FormFactor, Inc. (NASDAQ: FORM) shares gained 8.8 percent to $16.21.
DDR Corp (NYSE: DDR) climbed 8.8 percent to $8.66 after announcing the the creation of a retail value trust, which will be spun off with approximately $3 billion of Gross Book Value of assets and business. The company will complete the portfolio transformation while maintaining scale and balance sheet strength and that the strategy will realize private market asset values.
Galapagos NV (ADR) (NASDAQ: GLPG) shares gained 7.4 percent to $90.71 after the company reported that it has exercised co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries.
Hess Corp. (NYSE: HES) climbed 4.7 percent to $44.42 after a WSJ report says that activist investor Elliott seeks to replace John Hess as CEO or get him to consider a sale. The activist investor also seeks a dividend cut and more buybacks.
U.S. Global Investors, Inc. (NASDAQ: GROW) gained 4.6 percent to $5.915 after climbing 7.82 percent on Thursday.
RumbleON Inc (NASDAQ: RMBL) shares gained 3.1 percent to $5.4594 after announcing a strategic partnership with Sonic Automotive Inc (NYSE: SAH).

Losers
TrovaGene Inc (NASDAQ: TROV) shares dipped 43.1 percent to $0.2449. Trovagene priced its 15 million share common stock offering at $0.30 per share.
One Horizon Group Inc (NASDAQ: OHGI) shares dipped 21.1 percent to $2.4299 after surging 185.16 percent on Thursday.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares dropped 15.6 percent to $0.53 after the company agreed to be acquired by Genoptix for $10 million.
Verastem Inc (NASDAQ: VSTM) shares declined 12.1 percent to $3.21 after announcing public offering of common stock.
Frontier Communications Corp (NASDAQ: FTR) dropped 10 percent to $8.6401. Barclays initiated coverage on Frontier Communications with an Underweight rating and a $7.00 price target.
Fitbit Inc (NYSE: FIT) shares dropped 7.7 percent to $6.2950. Stifel Nicolaus downgraded Fitbit from Hold to Sell.
CSX Corporation (NYSE: CSX) dipped 7.7 percent to $52.88 following announcement that the CEO Hunter Harrison had taken medical leave.
Oracle Corporation (NYSE: ORCL) shares declined 5.6 percent to $47.37. Oracle posted upbeat earnings for its second quarter, but revenue from its cloud-based business missed analysts' estimates.
SG Blocks Inc (NASDAQ: SGBX) shares slipped 5.5 percent to $5.20.
Global Blood Therapeutics Inc (NASDAQ: GBT) fell 5.3 percent to $37.30. Global Blood Therapeutics reported a $100 million common stock offering.
bebe stores, inc. (NASDAQ: BEBE) shares fell 5.1 percent to $4.10.
Yield10 Bioscience Inc (NASDAQ: YTEN) shares dropped 5 percent to $3.45 after dropping 17.153 percent on Thursday.
The Chefs' Warehouse, Inc. (NASDAQ: CHEF) slipped 2.7 percent to $19.50 after the company reported commencement of public offering of common stock.

30 Stocks Moving In Friday's Mid-Day Session

ShiftPixy Inc (NASDAQ: PIXY) shares climbed 97 percent to $4.27 following Q4 earnings report. ShiftPixy reported sales of $20.244 million in the fourth quarter, up from $8.46 million year-over-year. The company sees first quarter gross billings of $40 million.
Longfin Corp (NASDAQ: LFIN) shares climbed 56.8 percent to $8.45 after the company announced agreement to acquire Ziddu.com.
Diana Containerships Inc (NASDAQ: DCIX) shares rose 22.59 percent to $5.97 after falling 7.06 percent on Thursday.
Riot Blockchain, Inc. (NASDAQ: RIOT) shares climbed 14.51 percent to $28.605 after gaining 8.47 percent on Thursday.
Wins Finance Holdings Inc (NASDAQ: WINS) shares gained 14.2 percent to $136.00.
Educational Development Corporation (NASDAQ: EDUC) shares rose 13.1 percent to $16.00 after the company reported Q3 and year-to-date revenue.
Crocs, Inc. (NASDAQ: CROX) climbed 12.4 percent to $12.30. Stifel Nicolaus upgraded Crocs from Hold to Buy.
TiGenix NV (NASDAQ: TIG) gained 12.4 percent to $24.36. Takeda and TiGenix disclosed that Cx601 has received a positive CHMP opinion for treatment of complex perianal fistulas in Crohn's disease. Mesoblast has granted Tigenix exclusive global patent license to use adipose-derived mesenchymal stem cells in local treatment of fistulae.
Marathon Patent Group Inc (NASDAQ: MARA) jumped 10.8 percent to $6.0206 after falling 4.57 percent on Thursday.
Professional Diversity Network Inc (NASDAQ: IPDN) shares rose 10 percent to $4.10.
Under Armour Inc (NYSE: UAA) shares jumped 9 percent to $15.06. Stifel Nicolaus upgraded Under Armour from Hold to Buy.
FormFactor, Inc. (NASDAQ: FORM) shares gained 8.8 percent to $16.21.
DDR Corp (NYSE: DDR) climbed 8.8 percent to $8.66 after announcing the the creation of a retail value trust, which will be spun off with approximately $3 billion of Gross Book Value of assets and business. The company will complete the portfolio transformation while maintaining scale and balance sheet strength and that the strategy will realize private market asset values.
Galapagos NV (ADR) (NASDAQ: GLPG) shares gained 7.4 percent to $90.71 after the company reported that it has exercised co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries.
Hess Corp. (NYSE: HES) climbed 4.7 percent to $44.42 after a WSJ report says that activist investor Elliott seeks to replace John Hess as CEO or get him to consider a sale. The activist investor also seeks a dividend cut and more buybacks.
U.S. Global Investors, Inc. (NASDAQ: GROW) gained 4.6 percent to $5.915 after climbing 7.82 percent on Thursday.
RumbleON Inc (NASDAQ: RMBL) shares gained 3.1 percent to $5.4594 after announcing a strategic partnership with Sonic Automotive Inc (NYSE: SAH).

Losers
TrovaGene Inc (NASDAQ: TROV) shares dipped 43.1 percent to $0.2449. Trovagene priced its 15 million share common stock offering at $0.30 per share.
One Horizon Group Inc (NASDAQ: OHGI) shares dipped 21.1 percent to $2.4299 after surging 185.16 percent on Thursday.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares dropped 15.6 percent to $0.53 after the company agreed to be acquired by Genoptix for $10 million.
Verastem Inc (NASDAQ: VSTM) shares declined 12.1 percent to $3.21 after announcing public offering of common stock.
Frontier Communications Corp (NASDAQ: FTR) dropped 10 percent to $8.6401. Barclays initiated coverage on Frontier Communications with an Underweight rating and a $7.00 price target.
Fitbit Inc (NYSE: FIT) shares dropped 7.7 percent to $6.2950. Stifel Nicolaus downgraded Fitbit from Hold to Sell.
CSX Corporation (NYSE: CSX) dipped 7.7 percent to $52.88 following announcement that the CEO Hunter Harrison had taken medical leave.
Oracle Corporation (NYSE: ORCL) shares declined 5.6 percent to $47.37. Oracle posted upbeat earnings for its second quarter, but revenue from its cloud-based business missed analysts' estimates.
SG Blocks Inc (NASDAQ: SGBX) shares slipped 5.5 percent to $5.20.
Global Blood Therapeutics Inc (NASDAQ: GBT) fell 5.3 percent to $37.30. Global Blood Therapeutics reported a $100 million common stock offering.
bebe stores, inc. (NASDAQ: BEBE) shares fell 5.1 percent to $4.10.
Yield10 Bioscience Inc (NASDAQ: YTEN) shares dropped 5 percent to $3.45 after dropping 17.153 percent on Thursday.
The Chefs' Warehouse, Inc. (NASDAQ: CHEF) slipped 2.7 percent to $19.50 after the company reported commencement of public offering of common stock.

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018

Few investments have the profit potential of penny stocks, which are stocks that trade under $5 per share.

Just take a look at Marathon Patent Group Inc. (Nasdaq: MARA), which climbed an astounding 341% during the four trading days of Thanksgiving week.

Biotech penny stocks are especially attractive since successful clinical trial results for their drugs can often send their share prices soaring 300%-plus.

That’s why today we’re giving you five of the top biotech penny stocks to buy that are all reporting clinical trial results in January 2018.

If a stock’s clinical trial results are positive, then the stock can soar. For example, the first stock on this list shot up 213% in July after the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for one of its drugs.

Receiving FDA approval for an NDA is typically the last major benchmark a drug must pass before it can be launched.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That’s why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you’re willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Now get comfy and grab your calendar, because here’s the first biotech penny stock on our list today…

Biotech Penny Stocks to Buy for January, No. 5: Aeterna Zentaris Inc.

Currently trading at $2 per share, Aeterna Zentaris (Nasdaq: AEZS) makes the drug Macrilen as a potential treatment for growth hormone deficiency in adults.

On July 18, the company announced the FDA accepted its NDA for Macrilen for review. This news sent AEZS shares up from $1.02 to $3.20 in just three trading days, for a gain of 213%.

top biotech penny stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine-75×113.png 75w, moneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine.png 300w” sizes=”(max-width: 200px) 100vw, 200px” title=”top biotech penny stocks to buy” />

Still, before Aeterna can launch the drug Macrilen, its resubmitted NDA must be approved by the FDA. The FDA will announce if it approves Aeterna’s resubmitted NDA on Dec. 30.

Company officials are confident the company will be able to launch Macrilen sometime in the first quarter of 2018.

Keep an eye on AEZS shares leading up to the Dec. 30 announcement, and buy only if you believe the FDA will approve the NDA.

Up next is a stock with a drug that has three chances to pass phase 3 clinical trials…

Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc.

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren’t “all in” on just one drug’s results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we’re going to focus on Axsome’s AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it’s likely that AXS-02’s results will come out first.

The next company we’ll show you is the cheapest on this list…

Biotech Penny Stocks to Buy for January, No. 3: BioLine Rx Ltd.

Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

Like Axsome Therapeutics, BioLine is less risky than other biotech penny stocks that only have a single drug in development or single partner. But BioLine’s risk profile is even more diverse, with eight drugs in development and multiple major partnerships to help support it.

The company’s leading drug BL-8040 is being tested in three different phase 2 clinical trials in 2018. The first trial is for the drug’s treatment of pancreatic cancer. Partial data of the trial will be presented between Jan. 18 and 20 at the ASCO 2018 Gastrointestinal Cancers Symposium.

Next up is a company which makes a drug that could provide millions of Americans with the relief they so deserve…

Join the conversation. Click here to jump to comments…

Come Talk About Bitcoin Next Week With Our All-Star Panel

Come Talk About Bitcoin Next Week With Our All-Star Panel

After striking new all-time highs in a matter of days, bitcoin trades three times higher than it did a month ago.

Bulls expect it to break $20,000 imminently, but the cryptocurrency’s fate is far from certain. Skeptics maintain the bitcoin bubble will burst amid the recent launch of futures, while agnostics confess enduring confusion.

To help make sense of the complicated trend, Benzinga will bring together some of the Street’s vying voices next week during the PreMarket Prep Bitcoin Special on Dec. 19.

What Can I Learn?

Co-hosts Joel Elconin and Dennis Dick will moderate an expert panel discussing the basics and complexities of cryptocurrency, including its potential to become a new asset class, the threat of a bubble, evaluation of fair price, the mechanics of mining, the effects of futures trading and the prospects of government regulation.

They will also weigh exposure opportunities in peripheral stocks and ETFs, including Riot Blockchain Inc (NASDAQ: RIOT), Social Reality Inc (NASDAQ: SRAX), Marathon Patent Group Inc (NASDAQ: MARA), Digital Power Corporation (NYSE: DPW) and Xunlei Ltd (NASDAQ: XNET).

Who Are The Guests?

The panel will feature experts with opposing perspectives on cryptocurrency:

Jeff Goldman, a long-time bitcoin trader and author of “Failed Traders: The 20 Common Mistakes Committed By Over 1,000 Losing Traders;”
Joe Saluzzi, bitcoin critic and partner and co-founder of Themis Trading;
Michael Graub, bitcoin trader through a private family office.
Peter Schiff, CEO and Chief Global Strategist at Euro Pacific Capital
Michael Sonnenshein, Investments Director at Grayscale, sponsor of the Bitcoin Investment Trust (OTC: GBTC)
Where and When?

The free webinar will run Tuesday, Dec. 19, from 8 a.m. to 9:30 a.m. EST. Register for the webinar here!

25 Stocks Moving In Friday's Mid-Day Session

American Woodmark Corporation (NASDAQ: AMWD) shares climbed 32 percent to $131.45. American Woodmark reported purchase of RSI Home Products for $1.075 billion in enterprise value and posted upbeat quarterly earnings.
Ambarella Inc (NASDAQ: AMBA) shares jumped 18 percent to $64.03 after the company reported stronger-than-expected results for its third quarter.
Foundation Medicine Inc (NASDAQ: FMI) shares climbed 16.4 percent to $61.92 after the FDA approved the company’s FoundationOne CDx Diagnostic test for solid tumors.
Nutanix Inc (NASDAQ: NTNX) shares jumped 15.3 percent to $37.83 after reporting a first quarter loss of 16 cents, 10 cents lower than analyst estimates. Sales came in $9 million higher than estimates at $275.6 million. The company issued better than expected second quarter earnings and sales guidance.
Marathon Patent Group Inc (NASDAQ: MARA) shares rose 10.26 percent to $4.60.
Titan Machinery Inc (NASDAQ: TITN) jumped 10.2 percent to $20.93.
Amira Nature Foods Ltd. (NYSE: ANFI) shares climbed 9.5 percent to $4.7601.
TapImmune, Inc. (NASDAQ: TPIV) shares rose 8.3 percent to $3.00.
Uniqure NV (NASDAQ: QURE) rose 6.3 percent to $16.09. Analysts at H.C. Wainwright initiated coverage on Uniqure with a Buy rating.
Global Blood Therapeutics Inc. (NASDAQ: GBT) jumped 5.5 percent to $41.60. H.C. Wainwright initiated coverage on Global Blood Therapeutics with a Buy rating.
Diana Containerships Inc. (NASDAQ: DCIX) shares gained 5.3 percent to $7.40.
UQM Technologies Inc (NYSE: UQM) gained 5.23 percent to $1.61 following news of a joint venture with China National Heavy Duty Truck Group late Thursday.
NoaBlue Apron Holdings Inc (NYSE: APRN) gained 5 percent to $3.14 after the company announced Co-Founder Matt Salzber has stepped down as President and CEO, naming Brad Dickerson as the new CEO.
Plug Power Inc (NASDAQ: PLUG) shares rose 4.01 percent to $2.46. Canaccord Genuity initiated coverage on Plug Power with a Buy rating and a $5.00 price target.

Losers
MER Telemanagement Solutions Ltd. (NASDAQ: MTSL) dropped 22.1 percent to $1.94 after the company posted Q3 results.
Genesco Inc. (NYSE: GCO) shares dipped 18.8 percent to $25.25 as the company reported downbeat quarterly earnings.
Zumiez Inc. (NASDAQ: ZUMZ) fell 13.8 percent to $18.80. Zumiez reported in-line earnings for its third quarter on Thursday.
Universal Technical Institute, Inc. (NYSE: UTI) shares dropped 13.6 percent to $3.18.
China Rapid Finance Ltd – ADR (NYSE: XRF) declined 10 percent to $6.70.
Pareteum Corp (NASDAQ: TEUM) shares fell 9.4 percent to $0.96.
Good Times Restaurants Inc. (NASDAQ: GTIM) shares dropped 8.2 percent to $2.25.
Ichor Holdings Ltd (NASDAQ: ICHR) fell 7.1 percent to $26.39.
Ulta Beauty Inc (NASDAQ: ULTA) fell 5.3 percent to $209.90. Ulta Beauty reported better-than-expected earnings for its third quarter. The company also saw comps up a whopping 10.3 percent in the quarter but issued weak fourth quarter earnings guidance.
Oxford Industries Inc (NYSE: OXM) dropped 4.7 percent to $65.73. Needham & Company downgraded Oxford Industries from Buy to Hold.
Cypress Semiconductor Corporation (NASDAQ: CY) fell 3.5 percent to $15.46. SunTrust Robinson Humphrey downgraded Cypress Semiconductor from Buy to Hold.